Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

“Due to the progressive nature of polyneuropathy of hereditary transthyretin-mediated amyloidosis, it is critical to have timely diagnosis and new therapies to help people have greater control over ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Hereditary transthyretin amyloidosis with polyneuropathy (damage to your peripheral nerves), (hATTR-PN), is a rare disease ...

A rabbit sensitized with myelin lipid galactocerebroside develops autoimmune demyelinating polyneuropathy. The nerve conduction study was performed prior to sensitization (a) and at the peak of ...

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by ...

Intellia Therapeutics Inc (NTLA) showcases strong financials and significant progress in its CRISPR-based pipeline, despite ...

In addition, we're making excellent progress across our other late-stage trials. As announced this morning, the FDA cleared ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary ...

According to analysts' consensus estimate, Intellia Therapeutics (NASDAQ: NTLA), a clinical-stage biotech, boasts a ...

(Alliance News) - AstraZeneca PLC on Monday said its Wainzua treatment has been been recommended for EU approval to treat adult patients with polyneuropathy associated with hereditary ...